


## Disclaimer

- This presentation has been prepared by Duni AB (the "Company") solely for use at this investor presentation and is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations.
- This presentation is not for presentation or transmission into the United States or to any U.S. person, as that term is defined under Regulation S promulgated under the Securities Act of 1933, as amended.
- This presentation contains various forward-looking statements that reflect management's current views with respect to future events and financial and operational performance. The words "believe," "expect," "anticipate," "intend," "may," "plan," "estimate," "should," "could," "aim," "target," "might," or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which are in some cases beyond the Company's control and may cause actual results or performance to differ materially from those expressed or implied from such forward-looking statements. These risks include but are not limited to the Company's ability to operate profitably, maintain its competitive position, to promote and improve its reputation and the awareness of the brands in its portfolio, to successfully operate its growth strategy and the impact of changes in pricing policies, political and regulatory developments in the markets in which the Company operates, and other risks.
- The information and opinions contained in this document are provided as at the date of this presentation and are subject to change without notice.
- No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company, or any of its principal shareholders or subsidiary undertakings or any of such person's officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

## 2012 Q3 Highlights

- Professional affected mainly by weak EUR
  - Volume declined by some 3% primarily reflecting a soft market in combination with less invoicing days in September (start of Christmas season).
  - Negative currency effects due to weak EUR.
- Consumer improved sales trend
  - Deliveries to new major accounts started during the quarter.
  - Roll out initially influencing EBIT negatively.
- Tissue
  - Low capacity utilization main explanation for weak result contrary to a strong quarter last year.
  - Test runs for new qualities.
- Cash flow remains strong, driven by normalized capital expenditure and activities to bring down seasonal stock level.

- Net sales SEK 849 m (917)
- Underlying operating income SEK 63 m (98)
- Underlying operating margin 7.4% (10.7%)



## **Market Outlook**

- HORECA market long-term growing in line or slightly above GDP
  - Positive eating out trend.
  - Higher growth in take-away sector.
- Negative macro statistics in majority of markets translates into softer demand.
  - European debt crises still creates uncertainty regarding economic recovery.
  - Key market Germany now facing negative growth figures for HoReCa.
- Pulp and energy lower than last year however input material for traded goods remain on high level.



#### HoReCa Sales development Germany (July 2012)


Wirtschaftsbereich	07/2012 zu	07/2011	01-07/2012 zu 01-07/2011		
	nominal	real	nominal	real	
Gastgewerbe insgesamt	-0,7	(-2,4)	2,1	0,0	
davon:			- 20		
Beherbergung	-0,1	-1,1	2,8	0,9	
Gastronomie	-1,1	-3,3	1,7	-0,5	

Source: destatis



## Restaurant Sales Development,

Sweden (Aug 2011 – Aug 2012)




 $\Box$  +5.4% in volume in Aug and +5,4% in value.





#### **Professional**

#### -Lower sales and EBIT mainly impacted by currency




#### Geographical split – sales Q3 2012

Net sales Professional	Q3 2012	Q3 2011	Growth	Growth at fixed exchange rates
Nordic	140	152	-7.9%	-7.2%
Central Europe	375	417	-10.1%	-2.6%
South & East Europe	111	119	-6.7%	0.8%
Rest of the World	9	8	12.5%	12.5%
TOTAL	635	696	-8.8%	-3.1%

- Loss of low end business in Denmark and Sweden impacted Nordic. Discontinued contracts in UK impacting Central Europe while development in Germany follows overall market trend.
- Russia main growth driver for South and East, while Italy and Spain hurt by economic recession.
- Evolin roll out continues.
- 1) Excluding non-recurring costs and market valuation of derivatives




## **Evolin Campaign**





## Consumer

#### Positive trend with growth in Central Region



#### Geographical split - sales Q3 2012

Net sales Consumer	Q3 2012	Q3 2011	Growth	Growth at fixed exchange rates
Nordic	15	16	-6.3%	-6.3%
Central Europe	84	90	-6.7%	1.1%
South & East Europe	2	4	-50.0%	-50.0%
Rest of the World	0	0	0.0%	0.0%
TOTAL	101	110	-8.2%	-1.6%


- Stagnating market in grocery retail trade.
- Central region positively impacted by implementation of new accounts. Roll out estimated to be finalized by year end.




<sup>1)</sup> Excluding non-recurring costs and market valuation of derivatives

## **Tissue**

#### Low capacity utilization









## Operating Margin 7.4%

SEKm	Q3 2012	Q3 2011	YTD 2012	YTD 2011	Q3 LTM	FY 2011
Net sales	849	917	2 638	2 744	3 701	3 807
Gross profit	207	248	678	716	993	1 031
Gross margin	24.3 %	27.1 %	25.7 %	26.1 %	26.8 %	27.1%
Selling expenses	-97	-105	-327	-332	-436	-441
Administrative expenses	-39	-43	-122	-128	-166	-172
R&D expenses	-5	-7	-20	-21	-29	-30
Other operating net	-4	4	-3	9	-11	0
Operating income (reported)	62	98	207	244	350	388
Non-recurring items <sup>1)</sup>	1	0	6	-9	-13	-16
Operating income (underlying)	63	98	212	253	363	404
Operating margin (underlying)	7.4 %	10.7 %	8.1 %	9.2 %	9.8 %	10.6 %
Financial net	-3	-8	-20	-20	-29	-30
Taxes	-11	-26	-46	-61	-83	-98
Net income	47	63	140	163	238	261
Earnings per share	1.01	1.34	2.98	3.46	5.07	5.54

<sup>1)</sup> Restructuring costs and market valuation of derivatives



## Quarter affected by FX effects and lower capacity utilization

SEKm		Q3 2012	Q3 2011	YTD 2012	YTD 2011	Q3 LTM	FY 2011
Professional	Net sales	635	696	1 959	2 016	2 709	2 766
	Operating income <sup>1)</sup>	77	93	228	237	349	357
	Operating margin	12.1%	13.3%	11.6%	11.7%	12.9%	12.9%
Consumer	Net sales	101	110	354	403	563	612
	Operating income <sup>1)</sup>	-12	-5	-13	-3	11	21
	Operating margin	-11.8%	-4.4%	-3.8%	-0.8%	2.0%	3.4%
Tissue	Net sales	112	111	325	324	429	428
	Operating income <sup>1)</sup>	-2	10	-2	20	3	25
	Operating margin	-2.2%	9.2%	-0.8%	6.1%	0.7%	5.9%
Duni	Net sales	849	917	2 638	2 744	3 701	3 807
	Operating income <sup>1)</sup>	63	98	212	253	363	404
	Operating margin	7.4%	10.7%	8.1%	9.2%	9.8%	10.6%



<sup>1)</sup> Excluding non-recurring cost and market valuation of derivates

# Strong Cash Flow: reduced stock building and lower capex

SEKm	Q3 2012	Q3 2011	YTD 2012	YTD 2011	Q3 LTM	FY 2011
EBITDA <sup>1)</sup> Capital expenditure	90	125 -58	296 -87	333 -177	473 -287	511 -377
Change in;	-21	-30	-07	-1//	-267	-3//
Inventory	-20	-66	-24	-92	31	-37
Accounts receivable	11	38	29	-23	16	-36
Accounts payable	-3	4	-19	-4	-23	-8
Other operating working capital	27	26	-1	46	-23	23
Change in working capital	-15	3	-15	-7 <b>4</b>	1	-58
Operating cash flow	84	70	194	83	187	76

<sup>1)</sup> Excluding non-recurring costs and market valuation of derivatives



## Net Debt at all time low for Q3

SEKm	Q3 2012	Q3 2011	FY 2011
Goodwill	1 199	1 199	1 199
Tangible and intangible fixed assets	870	728	888
Net financial assets <sup>1)</sup>	210	241	210
Inventories	481	534	470
Accounts receivable	604	670	663
Accounts payable	-270	-315	-302
Other operating assets and liabilities <sup>3)</sup>	-284	-323	-300
Net assets	2 810	2 734	2 827
Net debt	740	755	745
Equity	2 070	1 979	2 082
Equity and net debt	2 810	2 734	2 827
ROCE <sup>2)</sup>	14%	17%	17%
ROCE <sup>2)</sup> w/o Goodwill	26%	32%	29%
Net debt / Equity	36%	38%	36%
Net debt / EBITDA <sup>2)</sup>	1.6	1.5	1.5

<sup>1)</sup> Deferred tax assets and liabilities + Income tax receivables and payables



<sup>2)</sup> Excluding non-recurring costs and market valuation of derivatives

<sup>3)</sup> Including restructuring provision and derivatives

## Financial Targets

Q3 LTM 2012

-2,0%

Sales growth > 5%

Organic growth of 5% over a business cycle

(at fixed exchange rates)

 Consider acquisitions to reach new markets or to strengthen current market positions

EBIT margin > 10%

Top line growth – premium focus

9,8%

• Improvements in manufacturing, sourcing and logistics

Dividend payout ratio 40+%

Target at least 40% of net profit

3.50 SEK per share (2011)



